Korro Bio, Inc. Common Stock (KRRO) is a publicly traded Healthcare sector company. As of May 19, 2026, KRRO trades at $9.54 with a market cap of $146.82M and a P/E ratio of -0.85. KRRO moved -3.31% today. Year to date, KRRO is +23.85%; over the trailing twelve months it is -34.02%. Its 52-week range spans $5.20 to $98.00. Analyst consensus is strong buy with an average price target of $20.13. Rallies surfaces KRRO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Korro Bio Reports Over 90% SERPINA1 Editing and 95% Z-AAT Reduction with KRRO-111: Korro Bio added KRRO-111 as a development candidate for alpha-1 antitrypsin deficiency, reporting over 90% in vivo SERPINA1 transcript editing and ~90% functional AAT protein restoration in mouse models. In repeat-dose studies, a 3 mg/kg regimen reduced pathogenic Z-AAT production by ~95% and cleared existing aggregates by 69%.
| Metric | Value |
|---|---|
| Price | $9.54 |
| Market Cap | $146.82M |
| P/E Ratio | -0.85 |
| EPS | $-11.67 |
| Dividend Yield | 0.00% |
| 52-Week High | $98.00 |
| 52-Week Low | $5.20 |
| Volume | 52.20K |
| Avg Volume | 0 |
| Revenue (TTM) | $3.84M |
| Net Income | $-113.50M |
| Gross Margin | 0.00% |
9 analysts cover KRRO: 0 strong buy, 8 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $20.13.